Alterations in IL-6, IL-8, GM-CSF, TNF-α, and IFN-γ release by peripheral mononuclear cells in patients with active vitiligo

Journal of Investigative Dermatology

Volumn 108, Issue 4, 1997, Pages 527-529

  Yu, Hsin Su ^a   Chang, Kee Lung ^a   Yu, Chia Li ^b   Li, Hui Fang ^a   Wu, Meng Tse ^a   Wu, Chieh Shan ^a   Wu, Ching Shuang ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

cytokine; IgG anti melanocyte antibodies; vitiligo vulgaris

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 8; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; ANTIBODY; INTERLEUKIN DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; VITILIGO; BLOOD; FEMALE; IMMUNOLOGY; MALE; MELANOCYTE; METABOLISM;

ANTIBODIES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; INTERFERON TYPE II; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MELANOCYTES; PHYTOHEMAGGLUTININS; TUMOR NECROSIS FACTOR-ALPHA; VITILIGO;

EID: 85052661690     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/1523-1747.ep12289743     Document Type: Article

References (37)

1. Abdel-Naser MB, Ludwig W-D: Nonsegmental vitiligo: Decrease of the CD45RA+ T-cell subset and evidence for peripheral T-cell activation. Int J Dermatol 31:321-326, 1992
2. Al Badri AMT, Foulis AK, Todd PM, Garioch JJ, Gudgeon JE, Stewart DG, Gracie JA, Goudie RB: Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 169:203-206, 1993
3. Al-Fouzan A, Al-Arbash M, Fouad F, Kaaba SA, Mousa MA, Al-Harbi SA: Study of HLA class I/II and T lymphocyte subsets in Kuwaiti vitiligo patients. Eur J Immunogenet 22:209-213, 1995
4. Betterle C, Caretto A, De Zio A, Pedini B, Veller-Fornasa C, Cecchetto A, Acccordi F, Peserico A: Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica 171:419-423, 1985
5. Cunliffe WJ, Halder RM, Newell DJ: Vitiligo, thyroid disease and autoimmunity. Br J Dermatol 80:135-139, 1968
6. O'Amelio R, Frati C, Fatlorossi A, Aiuti F: Peripheral T-cell subset imbalance in patients with vitiligo and in their apparently healthy first-degree relatives. Ann Allergy 65:143-145, 1990
7. Grimes PE, Ghoneum M, Stockton T, Payne C, Kelly P, Alfred L: T cell profiles in vitiligo. J Am Acad Dermatol 14:196-201, 1986
8. Hann SK, Park YK: Chung KY, Kim HI, Im S, Won JH: Peripheral blood lymphocyte imbalance in Koreans with active vitiligo. Int J Dermatol 32:286-289, 1993
9. Harsoulas P, Kanakouki-Tsakalidis F, Vyzantiadis A, Minas A, Cassimos C: Autoimmunity and vitiligo. Arch Dermatol 114:1154-1157, 1978
10. Hegedus L, Heidenheim M, Gervil M, Hjalgrim H, Hoier-Madsen M: High frequency of thyroid dysfunction in patients with vitiligo. Acta Dermatol Venereol (Stockholm) 74:1211-123, 1994
11. Imokawa G, Yada Y, Kimura M, Morisaki N: Granulocyte/macrophage colony-stimulating factor is an intrinsic keratinocyte-derived growth factor for human melanocytes in UVA-induced melanosis. Biochem J 313:625-631, 1996
12. Kao CH, Yu HS: Depletion and repopulation of Langerhans cells in non-segmental type vitiligo. J Dermatol 17:287-296, 1990
13. Kao CH, Yu HS: A study of the effects of phorbol 12-myristate-13-acetate on cell differentiation of pure human melanocytes in vitro. Arch Dermatol Res 283:119-125, 1991
14. Kirnbauer R, Charvat B, Schauer K, Kock A, Urbanshi A, Forster E, Neuner P, Assmann I, Luger TA, Schwarz T: Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: Evidence for a regulatory role of IL-6, IL-7, TNF-α and UVB light. J Invest Dermatol 98:320-326, 1992
15. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
16. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K: The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243:1464-1466, 1989
17. Martz E: LFA-1 and other accessory molecules functioning in adhesions of T and B lymphocytes. Hum Immunobiol 18:3-37, 1987
18. Moellmann G, Klein-Angfrer S, Scollay DA, Nordlund JJ, Lerner AB: Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 79:321-330, 1982
19. Morelli JG, Norris DA: Influence of inflammatory mediators and cytokines on human melanocyte function. J Invest Dermatol 100:191s-195s, 1993
20. Mozzanica N, Frigerio U, Finzi F, Cattaneo A, Negri M, Scaglione F, Fraschini F, Foppa S: T cell subpopulations in vitiligo: A chronobiologic study. J Am Acad Dermatol 22:223-230, 1990
21. Mozzanica N, Frigerio LJ, Negri M, Tadini G, Villa ML, Mantovani M, Finzi AF: Circadian rhythm of natural killer cell activity in vitiligo. J Am Acad Dermatol 20:591-596, 1989
22. Mozzanica N, Villa ML, Foppa S, Vignati G, Cattaneo A, Diotti R, Finzi AF: Plasma α-melanocyte-stimulating hormone, β-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 26:693-700, 1992
23. Naughton GK, Eisinger M, Bystryn JC: Antibodies to normal human melanocytes in vitiligo. J Exp Med 158:246-251, 1983a
24. Naughton GK, Eisinger M, Bystryn JC: Detection of antibodies to melanocytes by specific immuno-precipitation. J Invest Dermatol 81:540-542, 1983b
25. Norris DA: Cytokine modulation of adhesion molecules in the regulation of immunologic cytotoxicity of epidermal targets. J Invest Dermatol 95:111s-120s, 1990
26. Norris DA, Kissinger PM, Naughton GM, Bystryn JC: Evidence for immunologic mechanism in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 90:783-789, 1988
27. Soubiran P, Benzaken S, Bellet C, Lacour JP, Ortonne JP: Vitiligo: peripheral T-cell subset imbalance as defined by monoclonal antibodies. Br J Dermatol 113(suppl 28):124-127, 1985
28. Taher-Uz-Zaman, Begum S, Waheed MA: In vitro assessment of 'T' lymphocyte functioning in vitiligo. Acta Dermato-Venereol (Stockholm) 72:266-267, 1992
29. Tracey KJ, Vlassara H, Cerami A: Cachectin/TNF (tumour necrosis factor) Lancet 1:1122-1126, 1989
30. Trinchieri G, Perussia B: Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 6:131-136, 1985
31. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A: Cachectin/TNF and IL-1 induced by glucose-modified protein: role in normal tissue remodeling. Science 240:1546-1548, 1988
32. Yohn JJ, Critelli M, Lyons MB, Norris DA: Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines. J Invest Dermatol 90:233-237, 1990
33. Yoshimura T, Matsushima K, Oppenheim JJ, Leonard EJ: Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL-1). J Immunol 139:788-793, 1987
34. Yu CL, Chang KL, Chiu CC, Chiang BN, Han SH, Wang SR: Alteration of mirogenic responses of mononuclear cells by anti-ds DNA antibodies resembling immune disorders in patients with systemic lupus erythematosus. Scand J Rheumatol 18:265-276, 1989b
35. Yu CL, Chang KL, Hong ST, Chiang BN, Han SH, Wang SR: Defective helper T cell function in IgM rheumatoid factor synthesis in patients with ankylosing spondylitis. Scand J Rheumatol 18:43-49, 1989a
36. Yu HS, Kao CH, Yu CL: Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 100:823-828, 1993
37. Zauli D, Tosti A, Biases G, Miserocchi F, Patrizi A, Azzaroni D, Andriani G, Di Febo G, Callegari C: Prevalence of autoimmune atrophic gastritis in vitiligo. Digestion 34:169-172, 1986.